CCI approves the acquisition of Intas Pharmaceuticals Limited by Canary Investments


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ medicircle-cci-approves-the-acquisition-of-intas-pharmaceuticals-limited-by-canary-investments
The Proposed Combination relates to acquisition of less than 5% shareholding ofIntas Pharmaceuticals Limited (Intas) by Canary Investments Limited (Canary) and Link Investment Trust II (Link II).

The Competition Commission of India (CCI) approves the acquisition of less than 5% shareholding in Intas Pharmaceuticals Limited by Canary Investments Limited and Link Investment Trust II, under Section 31(1) of the Competition Act, 2002.

The Proposed Combination relates to acquisition of less than 5% shareholding ofIntas Pharmaceuticals Limited (Intas) by Canary Investments Limited (Canary) and Link Investment Trust II (Link II).

Canary is an investment company registered in Mauritius. Link II is a private trust created and registered under the laws of India.Intas is a public limited company incorporated and registered under the laws of India. Intas is said to be a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company.

The Commission approved the Proposed Combination subject to the carrying out of modifications proposed by Canary and Link II.

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world.

Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas’ remarkable success in North America and European operations have helped us emerge as a global brand in the world’s largest pharmaceutical markets.


All products are manufactured in facilities that are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA and more. Today, a segment-leading pipeline and strong in-house development capabilities allow Intas to compete with some of the biggest portfolios in the industry. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities and is set to continue raising the bar of healthcare excellence, globally in the near future.

Tags : #IntasPharmaceuticals #CanaryInvestments #CCI #Acquisition

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026